Lab-on-a-chip nanoarchitectures for oncogene detection and early cancer screening
Frontiers in Nanotechnology · 17.03.2026 · 8
DOI: 10.3389/fnano.2026.1796554 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Nanotechnology, online erschienen am 17.03.2026. Verfasst von Niraj Singh und 4 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The global demand for precise and efficient cancer cell detection in biomedical and clinical diagnostics has catalysed significant innovation in micro- and nanotechnology-based analytical systems. The lab-on-a-chip (LOC) nanoarchitectures are powerful tools for high-throughput, non-invasive separation, detection, and classification of individual cancer cells. Thus, in oncology, cancer-on-a-chip models allow detection of tumour cell behaviour, including cellular interactions, angiogenesis, invasion, and metastasis across multiple organs. These devices are made up of nanoscale materials and microfluidic control, allowing real-time analysis of biological entities. These miniaturised systems can be used in-situ and have a portable sensing facility for bedside diagnosis. This facility significantly improves clinical outcomes and reduces mortality rates. The integration of nanomaterials such as gold nanoparticles, graphene, and quantum dots within microfluidic biochips enhances molecular recognition and signal transduction. Among these, electrochemical biosensors represent the most sensitive type of devices, capable of detecting biomolecules at trace or even atomic-level concentrations. The immuno-biochips that detect exosomal RNAs help to understand the tumour microenvironment and metastasis mechanisms. LOC devices that have optical, plasmonic, and dielectrophoretic detection techniques allow label-free, multiplexed analysis of circulating tumour cells and oncogene mutation, along with their expression profiles. Nanomaterial-based biosensing chips are rapid, sensitive, and miniaturised alternatives for oncogene detection and cancer diagnosis. Despite substantial progress, issues such as reproducibility, large-scale clinical validation, standardisation, and regulatory compliance continue to create barriers for these platforms to be regularly used in clinical practice. This review provides a critical assessment of nanoengineered lab-on-a-chip architectures for oncogene detection and systematically compares electrochemical and optical sensing approaches. It also discusses strategies to promote their integration into precision oncology and clinical diagnostic workflows.
Zitieren
APA
Singh, N., Priyadarshi, N., Ingti, B., Paul, P., & Das, D. (2026). Lab-on-a-chip nanoarchitectures for oncogene detection and early cancer screening. Frontiers in Nanotechnology, 8. https://doi.org/10.3389/fnano.2026.1796554
Vancouver
Singh N, Priyadarshi N, Ingti B, Paul P, Das D. Lab-on-a-chip nanoarchitectures for oncogene detection and early cancer screening. Frontiers in Nanotechnology. 2026;8. doi:10.3389/fnano.2026.1796554
BibTeX
@article{Singh2026,
author = {Singh, Niraj and Priyadarshi, Nitesh and Ingti, Birson and Paul, Payel and Das, Dipayan},
title = {Lab-on-a-chip nanoarchitectures for oncogene detection and early cancer screening},
journal = {Frontiers in Nanotechnology},
year = {2026},
volume = {8},
doi = {10.3389/fnano.2026.1796554}
}
EUVIMED